FDA Recall Highlights Sterility Risks for OASIS Medical's Ophthalmic Supply Chain
OASIS Medical, Inc. has initiated a Class II recall of its "Oasis Tears PF" (Glycerin) lubricant eye drops nationwide, prompted by FDA observations regarding sterility assurance at its French manufacturer, Excelvision. This event underscores critical supply chain vulnerabilities in sterile ophthalmic products. Procurement and regulatory teams must immediately assess their reliance on contract manufacturers for sterile drug products and diversify sourcing to mitigate sterility-related recall risks.
What the FDA Found: Sterility Assurance Deficiencies Trigger Recall
The U.S. Food and Drug Administration (FDA) observations at Excelvision, the French manufacturer for OASIS Medical, Inc.'s "Oasis Tears PF" lubricant eye drops, have directly led to a nationwide Class II voluntary recall of the product. The core issue identified is a "Lack of Assurance of Sterility" for this crucial ophthalmic product, which contains Glycerin as its active pharmaceutical ingredient (API). This deficiency was significant enough to prompt OASIS Medical, Inc. to initiate the recall on April 27, 2026, with the FDA classifying it on May 8, 2026, and reporting it on May 20, 2026. The recall specifically impacts Lot # 1V59 (Exp Date: 05/31/26) and Lots # 3V12, 3V69 (Exp Date: 08/31/26), distributed across the United States. For procurement directors, this incident highlights the paramount importance of robust quality agreements and rigorous oversight of contract manufacturing organizations (CMOs), particularly for sterile products. A breakdown in sterility assurance at a third-party facility, even one located internationally, directly translates into immediate supply disruptions and significant recall costs for the brand owner. Regulatory affairs heads must recognize that FDA scrutiny extends beyond the direct marketing authorization holder to the entire manufacturing network, demanding comprehensive audit programs and proactive remediation strategies to prevent similar market withdrawals. This event underscores that the responsibility for product quality and patient safety ultimately rests with the recalling firm, OASIS Medical, Inc., even when manufacturing is outsourced.
Manufacturing Footprint: Excelvision's Role in Ophthalmic Production
The "Oasis Tears PF" product, a preservative-free lubricant eye drop containing Glycerin, is marketed by OASIS Medical, Inc., based in Glendora, CA, United States. However, the product explicitly states "Made in France," and the FDA observations that triggered this recall were specifically noted during an inspection of Excelvision, indicating Excelvision as the contract manufacturer. While the precise facility location of Excelvision in France is not detailed in the available information, its role as a manufacturer of sterile ophthalmic products is now under intense regulatory spotlight. The product's National Drug Code (NDC) is 42126-6400-1, and its application number is M018, identifying it as a human OTC drug. For business development executives and supply chain VPs, this situation underscores the inherent risks associated with geographically dispersed manufacturing networks, especially when critical quality attributes like sterility are involved. Relying on a single contract manufacturer for a key product line, particularly one located in a different regulatory jurisdiction, introduces complexity in oversight and response. Any issues at the manufacturing site, such as those observed at Excelvision, directly jeopardize the market availability and brand reputation of the distributing company, OASIS Medical, Inc. Companies must evaluate their dependency on specific manufacturing sites and understand the regulatory compliance history and capabilities of their international partners to safeguard against supply chain disruptions stemming from manufacturing quality deficiencies.
Supply Chain Exposure: Nationwide Impact of Ophthalmic Sterility Breach
The Class II recall of "Oasis Tears PF" lubricant eye drops, distributed nationwide within the United States, signifies a substantial disruption for both healthcare providers and consumers relying on this specific preservative-free ophthalmic solution. As a human OTC drug containing Glycerin, "Oasis Tears PF" addresses a common need for dry eye relief, making its sudden withdrawal impactful across the retail pharmacy and ophthalmology sectors. The recall number D-0525-2026 confirms the FDA's classification of this event, which suggests that while the probability of serious adverse health consequences is remote, it is not negligible. The product's generic name is Glycerin, and its brand name is OASIS TEARS PF. For procurement directors, this event necessitates an immediate review of all ophthalmic product portfolios, particularly those sourced from third-party manufacturers or involving sterile formulations. The lack of sterility assurance is a critical failure that can lead to severe patient outcomes, including infections. This recall creates an urgent need to identify alternative suppliers for Glycerin-based ophthalmic lubricants or similar products to ensure continuity of supply. Business development executives must assess the competitive landscape for preservative-free eye drops and identify opportunities or threats arising from this market disruption. Furthermore, regulatory affairs teams should anticipate increased scrutiny on sterility data and manufacturing controls for all ophthalmic products, potentially leading to more stringent audit requirements for their own supply chains.
Alternative Sourcing Strategies for Sterile Ophthalmic APIs
While the ChemLifeIntel Knowledge Graph does not provide specific alternative suppliers for Glycerin-based ophthalmic products or contract manufacturers for sterile eye drops, this recall serves as a critical prompt for procurement teams to proactively identify and qualify diversified sourcing options. Given the "Lack of Assurance of Sterility" observed at Excelvision, companies relying on outsourced sterile manufacturing must immediately initiate a comprehensive risk assessment of their current supplier base. Key considerations include the manufacturing facility's regulatory history, its adherence to current Good Manufacturing Practices (cGMP), and its track record with regulatory bodies like the FDA. For supply chain VPs, the absence of readily available alternative supplier data in such a crisis underscores the imperative for strategic supplier relationship management and contingency planning. Diversifying the manufacturing footprint across different geographies and regulatory environments can mitigate the impact of single-point failures. Companies should explore contract development and manufacturing organizations (CDMOs) with proven expertise in sterile fill-finish operations and a robust quality system. Qualification timelines for new sterile drug product manufacturers can be extensive, often ranging from 12 to 24 months, including site audits, process validation, and regulatory filings. Therefore, proactive engagement with potential alternative suppliers is not merely a reactive measure but a fundamental component of resilient supply chain management, ensuring that products like Glycerin-based ophthalmic solutions remain available to patients without interruption.
Broader Industry Context: Sterility Concerns Across Pharmaceutical Manufacturing
The current recall initiated by OASIS Medical, Inc. due to sterility assurance issues at Excelvision, while specific to "Oasis Tears PF," is not an isolated incident within the broader pharmaceutical industry. The ChemLifeIntel Knowledge Graph indicates several recent parallel events highlighting persistent challenges with sterility and quality control. For instance, in June 2026 alone, Essential Wellness Pharma faced a Class II recall for its Progesterone Injection due to sterility assurance failures, and Spectra Medical Devices experienced a Class II recall for Lidocaine HCl Injection, also citing sterility assurance deficiencies. These events, alongside Guardian Drug Co. Inc.'s recalls for metallic contamination in antacids, collectively paint a picture of heightened regulatory scrutiny on manufacturing quality across various drug product categories. For regulatory affairs heads and business development executives, this trend signals an environment of increased risk and stricter enforcement from the FDA. The repeated occurrence of sterility-related recalls across different companies and product types (e.g., injectables, ophthalmic solutions) suggests systemic vulnerabilities in manufacturing processes, quality management systems, or contract manufacturer oversight. Companies must interpret these parallel events not as isolated incidents but as indicators of evolving regulatory expectations and potential areas for future FDA focus. Proactive investment in advanced aseptic processing technologies, enhanced environmental monitoring, and comprehensive supplier qualification programs are no longer optional but essential for maintaining market access and avoiding costly recalls that erode brand trust and market share. This broader context emphasizes the need for continuous improvement in quality systems to meet stringent regulatory demands.
Remediation and Future Outlook for Ophthalmic Supply
Following this Class II recall (D-0525-2026), OASIS Medical, Inc. is now responsible for ensuring comprehensive remediation actions are undertaken, both internally and at its contract manufacturing partner, Excelvision. The "Ongoing" status of the recall indicates that the process of retrieving affected product lots (Lot # 1V59, 3V12, 3V69) from the nationwide distribution network is still in progress. The FDA will expect a thorough investigation into the root cause of the "Lack of Assurance of Sterility" at the French manufacturing facility, followed by corrective and preventive actions (CAPAs) that address the identified deficiencies. This typically involves detailed reports, potential re-inspections, and verification of implemented controls to prevent recurrence. For supply chain VPs and procurement directors, the immediate future involves navigating the supply gap created by this recall for "Oasis Tears PF" (Glycerin). Companies must closely monitor OASIS Medical, Inc.'s communication regarding product availability and the resolution of the manufacturing issues at Excelvision. The long-term outlook depends on the efficacy of Excelvision's remediation efforts and the FDA's satisfaction with these actions. Failure to adequately address sterility concerns could lead to further regulatory actions, including potential import alerts for products manufactured at Excelvision, which would severely restrict market access to the U.S. This situation underscores the critical need for proactive risk management, including dual-sourcing strategies and robust quality oversight of all manufacturing partners, to safeguard the continuous supply of essential ophthalmic products.